Dmard

Tofacitinib for psoriatic arthritis is efficacious in most patient-reported and clinical endpoints over time, and shows shorter initial and meaningful response times versus switching from placebo to the drug at month 3, noted researchers.

The American College of Rheumatology has released two updated guideline papers for the treatment and management of juvenile idiopathic arthritis, according to a press release.

A machine learning model combining pharmacogenomic biomarkers with baseline DAS28 joint count predicted methotrexate response in early rheumatoid arthritis, according to data published in Arthritis Care & Research.

DMARD interruptions in patients with autoimmune rheumatic diseases increased more than 80% between December 2020 and May 2021, leading to higher rates of self-reported flares, according to data published in Arthritis Care & Research.

Despite a significant decrease in anxiety related to COVID-19, patients with autoimmune rheumatic disease continue to experience frequent interruptions in their medication use, according to survey data presented at ACR Convergence 2021.

In this video, Dana DiRenzo, MD, MHS, instructor of medicine at Johns Hopkins, discussed a session on the new ACR recommendations for managing patients with rheumatoid arthritis.

Patients with rheumatoid arthritis who fail their first JAK inhibitor can achieve success with either “cycling” to another JAK inhibitor or switching to a biologic disease-modifying antirheumatic drug, according to data presented at ACR Convergence 2021.

In an extension of the REDO trial, most patients with rheumatoid arthritis on ultra-low-dose rituximab — either 200 or 500 mg — maintained low disease activity for up to 4 years, according to data presented at ACR Convergence 2021.

Early, aggressive treatment with a biologic alongside a conventional DMARDs for juvenile idiopathic arthritis achieved clinically inactive disease at 24 months more frequently than other strategies, said a presenter at ACR Convergence 2021.

Approximately half of patients who reduced their disease-modifying antirheumatic drugs while in stable rheumatoid arthritis remission maintained their remission status, according to data published in The Lancet Rheumatology.